Navigation Links
BD Announces Results for Third Fiscal Quarter
Date:7/30/2009

FRANKLIN LAKES, N.J., July 30 /PRNewswire-FirstCall/ -- BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of $1.820 billion for the third fiscal quarter ended June 30, 2009, representing a decrease of 1.6 percent from the prior-year period. Excluding the unfavorable impact from foreign currency translation, which overall is estimated to account for 7 percentage points, worldwide revenues increased 5 percent.

"We are pleased with our solid third quarter performance and, in particular, the results achieved by our Diagnostics segment and our Medical segment's Pharmaceutical Systems and Diabetes Care units," stated Edward J. Ludwig, Chairman and Chief Executive Officer. "In the face of a challenging global economy, we exceeded our overall expectations in the quarter and, as a result, we are revising our revenue and earnings guidance to the high end of the range previously provided for this year. We remain confident that our focus on productivity improvements and disciplined expense management, along with our ongoing investments in long-term growth opportunities, will ensure BD's future success."

Analyses of Third Quarter and Nine-Month Period of Fiscal Year 2009 and 2008 Earnings

    Table 1         Three Months Ended June 30,   Nine Months Ended June 30,
    -------        ----------------------------  ---------------------------
                     2009     2008   % Growth      2009     2008   % Growth
                   -------  ------   --------    -------  ------   --------
    Diluted EPS    $ 1.39   $ 1.18     17.8%     $ 3.70   $ 3.34     10.8%
    Home
     Healthcare
     Divestiture    (0.01)       -                (0.03)   (0.03)
                   -------  ------               -------  ------
    Diluted EPS
     from
     Continuing
     Operations    $ 1.38   $ 1.18     16.9%     $ 3.67   $ 3.31     10.9%
    Specified
     Items:
      Litigation
       Charge (1)       -        -                 0.11        -
      Tax
       Adjustment
       (2)          (0.08)       -                (0.08)       -
                   -------  ------               -------  ------
    Adjusted
     Diluted EPS
     from
     Continuing
     Operations    $ 1.30   $ 1.18     10.2%     $ 3.70   $ 3.31     11.8%
                   =======  ======               =======  ======

    (1) Represents the charge relating to the pending settlement with the
        direct purchaser plaintiffs (which includes BD's distributors) in
        the antitrust class actions.
    (2) Represents the tax benefit relating to various tax settlements in
        multiple jurisdictions.

The preceding analysis (Table 1) of diluted earnings per share from continuing operations for the three-month and nine-month periods ended June 30, 2009 and 2008 identifies the specified items that affect comparability of results between periods. As illustrated, third quarter fiscal 2009 diluted earnings per share from continuing operations included a tax benefit of $20 million (8 cents diluted earnings per share from continuing operations) relating to various tax settlements in multiple jurisdictions. Excluding the tax benefit of 8 cents, third quarter fiscal 2009 diluted earnings per share from continuing operations were $1.30, representing an increase of 10 percent over diluted earnings per share from continuing operations of $1.18 from the prior-year period. Reported diluted earnings per share from continuing operations for the third quarter of fiscal 2009 included a 7-cents gain from our hedging program.

For the nine-month period, diluted earnings per share from continuing operations of $3.67 included the aforementioned tax benefit of 8 cents and the second quarter charge of 11 cents relating to a pending antitrust class action settlement. Excluding these specified items, diluted earnings per share from continuing operations for the nine-month period in fiscal year 2009 were $3.70, representing an increase of 12 percent over diluted earnings per share from continuing operations of $3.31 from the prior-year period. Reported diluted earnings per share from continuing operations for the nine-month period ending June 30, 2009 included a 23-cents gain from our hedging program.

Home Healthcare Product Line Sold

In July 2009, the Company sold the assets associated with its Home Healthcare product line to 3M, including product inventory, brand names and manufacturing associated with ACE((R)), Tensor((R)), Bauer & Black((R) )and Tru-Fit((R)) products, and thermometers. Consequently, the results of operations of the Home Healthcare product line have been classified as discontinued operations for all quarters and years referred to in this release. Included in the attached financial tables are the Company's Consolidated Income Statements for the first two quarters of fiscal year 2009 and for all periods in fiscal year 2008, which reflect this classification change. The Company expects to record a gain on the sale of about 5 cents diluted earnings per share from discontinued operations in the fourth fiscal quarter.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were $969 million, representing a decrease of 3 percent from the prior year period. Excluding the unfavorable impact from foreign currency translation of an estimated 8 percentage points, revenues increased 5 percent in the quarter due in part to sales of insulin delivery products, as well as safety-engineered and prefillable devices. For the nine-month period ended June 30, 2009 the BD Medical segment reported a 2 percent decrease in revenue growth. On a currency neutral basis, BD Medical revenues for the nine-month period increased by 3 percent.

In the BD Diagnostics segment, worldwide revenues for the quarter were $566 million, representing an increase of 2 percent from the prior year period. Excluding the unfavorable impact from foreign currency translation of an estimated 6 percentage points, revenues increased 8 percent in the quarter. Sales of safety-engineered devices, cancer diagnostics products and infectious disease testing systems, including flu-related products, contributed to revenue growth. For the nine-month period ended June 30, 2009 the BD Diagnostics segment reported 2.5 percent revenue growth. On a currency neutral basis, BD Diagnostics revenues for the nine-month period increased by 6.5 percent.

In the BD Biosciences segment, worldwide revenues for the quarter were $285 million, representing a decrease of 4 percent from the prior year period. Excluding the unfavorable impact from foreign currency translation of an estimated 3 percentage points, revenues decreased 1 percent in the quarter. Demand in the U.S. for capital equipment in the research and clinical segments continued to be impacted by funding constraints. International revenue growth moderated in the third quarter primarily due to lessening demand for instruments in Europe and Japan. For the nine-month period ended June 30, 2009 the BD Biosciences segment reported 3 percent revenue growth. On a currency neutral basis, BD Biosciences revenues for the nine-month period increased by 4 percent.

Geographic Results

Third quarter revenues in the U.S. were $805 million, representing an increase of 3 percent from the prior year period. Revenues outside of the U.S. were $1.015 billion, representing a decrease of 5 percent from the prior year period, and reflect an estimated 11 percentage points of unfavorable impact from foreign currency translation.

For the nine-month period ended June 30, 2009, revenues in the U.S. were $2.365 billion, representing an increase of 2 percent from the prior year period. Revenues outside of the U.S. were $2.898 billion, representing a decrease of 1 percent from the prior year period, and reflect an estimated 8 percentage points of unfavorable impact from foreign currency translation.

Fiscal 2009 Outlook for Full Year

The Company revised its guidance for full fiscal year 2009 reported diluted earnings per share from continuing operations to approximately 11 to 12 percent over diluted earnings per share from continuing operations of $4.42 for the full fiscal year 2008. The Company's guidance for full fiscal year 2009 includes an approximate 28-cents gain from our hedging program as discussed on our April 28, 2009 second fiscal quarter conference call.

The following analysis of estimated diluted earnings per share from continuing operations for the full fiscal year identifies specified items that affect the comparability of results between periods. As illustrated in Table 2, the Company expects that diluted earnings per share from continuing operations for the full fiscal year 2009, excluding specified items, will be approximately $4.92 to $4.96, representing an increase of approximately 11 to 12 percent over diluted earnings per share from continuing operations of $4.42 for the fiscal year 2008.

    Table 2                    Twelve Months Ended September 30,
    -------                  ------------------------------------
                                   2009        2008     % Growth
                             --------------  -------    --------
                               (Estimated)
    Diluted EPS (1)          $4.93 - $4.97   $ 4.46     10 - 11%
    Home Healthcare
     Divestiture                     (0.04)   (0.04)
                             --------------  -------
    Diluted EPS from
     Continuing Operations   $4.89 - $4.93   $ 4.42     11 - 12%
    Specified Items:
      Litigation Charge (2)          0 .11        -
      Tax Adjustment (3)             (0.08)       -
                             --------------  -------
    Adjusted Diluted EPS
     from Continuing
     Operations              $4.92 - $4.96   $ 4.42     11 - 12%
                             =============   =======

    (1) Does not include estimated gain on sale of Home Healthcare
        of about 5 cents.
    (2) Represents the charge relating to the pending settlement
        with the direct purchaser plaintiffs (which includes BD's
        distributors) in the antitrust class actions.
    (3) Represents the tax benefit relating to various tax
        settlements in multiple jurisdictions.

Conference Call Information

A conference call regarding BD's third fiscal quarter results, its expectations for the full fiscal year 2009 and its preliminary outlook for fiscal year 2010 will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET) Thursday, July 30, 2009. The conference call will be available for replay on BD's website, www.bd.com/investors, or at 800-642-1687 (domestic) and 706-645-9291 (international), Conference ID: 16834521, through the close of business on Thursday, August 6, 2009.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2009 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates, particularly in light of increased volatility in currency exchange rates; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; changes in healthcare or other governmental regulation, including changes in government pricing and reimbursement policies or other cost containment reforms; and issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per share data)

                                               Three Months Ended June 30,
                                              2009        2008       % Change
                                              ----        ----       --------
    REVENUES                              $1,820,255  $1,849,339         (1.6)

    Cost of products sold                    860,063     905,388         (5.0)
    Selling and administrative               429,940     435,807         (1.3)
    Research and development                  98,489      99,928         (1.4)
    -------------------------------------     ------      ------         ----
    TOTAL OPERATING COSTS
     AND EXPENSES                          1,388,492   1,441,123         (3.7)
    -------------------------------------  ---------   ---------         ----

    OPERATING INCOME                         431,763     408,216          5.8

    Interest income                           12,767      10,956         16.5
    Interest expense                         (11,288)     (9,017)        25.2
    Other expense, net                        (4,247)     (1,285)          NM
    -------------------------------------     ------      ------           --

    INCOME FROM CONTINUING OPERATIONS
     BEFORE INCOME TAXES                     428,995     408,870          4.9

    Income tax provision                      90,291     112,875        (20.0)
    -------------------------------------     ------     -------        -----

    INCOME FROM CONTINUING OPERATIONS        338,704     295,995         14.4

    INCOME FROM DISCONTINUED OPERATIONS
     NET OF INCOME TAX PROVISION (BENEFIT)
      OF $214 AND $(261), RESPECTIVELY         2,323       1,094           NM
    -------------------------------------      -----       -----           --

    NET INCOME                              $341,027    $297,089         14.8
    -------------------------------------   --------    --------         ----

    EARNINGS PER SHARE

    Basic:
    Income from continuing operations          $1.41       $1.21         16.5
    Income from discontinued operations        $0.01          $-           NM
    Net income (1)                             $1.42       $1.22         16.4

    Diluted:
    Income from continuing operations          $1.38       $1.18         16.9
    Income from discontinued operations        $0.01          $-           NM
    Net income                                 $1.39       $1.18         17.8


    AVERAGE SHARES OUTSTANDING

     Basic                                   240,109     244,273
     Diluted                                 245,696     251,648
    -------------------------------------    -------     -------

    NM - Not Meaningful

    (1) Total per share amounts may not add due to rounding



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    (Unaudited; Amounts in thousands, except per share data)

                                         Three Months Ended June 30, 2009
                                    ------------------------------------------
                                                       Tax         Excluding
                                    As Reported    Adjustment (1)     Item
                                    -----------    -------------   -----------

    Income taxes                        90,291            20,485      110,776
       effective tax rate                 21.0%                          25.8%

    Income from continuing
     operations                        338,704           (20,485)     318,219
       as a % of revenues                 18.6%                          17.5%

    Diluted earnings per share
    --------------------------
    Income from continuing
     operations                          $1.38            $(0.08)       $1.30

    (1) Represents the tax benefit relating to various tax settlements in
        multiple jurisdictions.



    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS
    (Unaudited; Amounts in thousands, except per share data)

                                               Nine Months ended June 30,
                                            2009        2008        % Change
                                            ----        ----        --------

    REVENUES                              $5,263,141  $5,262,786       0.0

    Cost of products sold                  2,485,687   2,566,465      (3.1)
    Selling and administrative             1,272,318   1,263,212       0.7
    Research and development                 294,391     287,169       2.5
    -----------------------------------      -------     -------       ---
    TOTAL OPERATING COSTS
     AND EXPENSES                          4,052,396   4,116,846      (1.6)
    -----------------------------------    ---------   ---------      ----

    OPERATING INCOME                       1,210,745   1,145,940       5.7

    Interest income                           18,730      32,489     (42.3)
    Interest expense                         (26,607)    (27,455)     (3.1)
    Other (expense) income, net                 (538)        252        NM
    -----------------------------------         ----         ---        --

    INCOME FROM CONTINUING OPERATIONS
     BEFORE INCOME TAXES                   1,202,330   1,151,226       4.4

    Income tax provision                     295,033     314,321      (6.1)
    -----------------------------------      -------     -------      ----

    INCOME FROM CONTINUING OPERATIONS        907,297     836,905       8.4

    INCOME FROM DISCONTINUED OPERATIONS
       NET OF INCOME TAX PROVISION OF
       $1,681 AND $1,364, RESPECTIVELY         7,086       7,916     (10.5)
    -----------------------------------        -----       -----     -----

    NET INCOME                              $914,383    $844,821       8.2
    -----------------------------------     --------    --------       ---

    EARNINGS PER SHARE

    Basic:
    Income from continuing operations          $3.77       $3.42      10.2
    Income from discontinued operations        $0.03       $0.03         -
    Net income (1)                             $3.80       $3.46       9.8

    Diluted:
    Income from continuing operations          $3.67       $3.31      10.9
    Income from discontinued operations        $0.03       $0.03         -
    Net income                                 $3.70       $3.34      10.8


    AVERAGE SHARES OUTSTANDING

     Basic                                    240,923    244,478
     Diluted                                  247,083    252,944
     ----------------------------------       -------    -------

    NM - Not Meaningful

    (1) Total per share amounts may not add due to rounding



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    (Unaudited; Amounts in thousands, except per share data)

                                      Nine Months ended June 30, 2009
                             -------------------------------------------------
                                 As      Litigation      Tax         Excluding
                              Reported    Charge (1)  Adjustment(2)    Items
                             ----------  -----------  ------------   ---------
    Selling and
     administrative          $1,272,318    $(45,000)         $-    $1,227,318
      as a % of revenues           24.2%                                 23.3%

    Operating Income          1,210,745      45,000           -     1,255,745
      as a % of revenues           23.0%                                 23.9%

    Income taxes                 295,033     17,100      20,485       332,618
      effective tax rate           24.5%                                 26.7%

    Income from continuing
     operations                  907,297     27,900     (20,485)      914,712
      as a % of revenues            17.2%                                17.4%

    Diluted earnings per share
    --------------------------
    Income from continuing
     operations                    $3.67      $0.11      $(0.08)        $3.70

    (1) Represents the charge relating to the pending settlement with the
        direct purchaser plaintiffs (which includes BD's distributors)
        in the antitrust class actions.
    (2) Represents the tax benefit relating to various tax settlements in
        multiple jurisdictions.



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)

                                             Three Months Ended June 30,
                                         2009             2008        % Change
                                         ----             ----        --------
    BD MEDICAL
    --------------
     United States                     $397,898         $386,724          2.9
     International                      570,773          611,424         (6.6)
    --------------                      -------          -------         ----
    TOTAL                              $968,671         $998,148         (3.0)
    --------------                     --------         --------         ----

    BD DIAGNOSTICS
    --------------
     United States                     $299,374         $280,118          6.9
     International                      267,005          273,304         (2.3)
    --------------                      -------          -------         ----
    TOTAL                              $566,379         $553,422          2.3
    --------------                     --------         --------          ---

    BD BIOSCIENCES
    --------------
     United States                     $108,136         $116,239         (7.0)
     International                      177,069          181,530         (2.5)
    --------------                      -------          -------         ----
    TOTAL                              $285,205         $297,769         (4.2)
    --------------                     --------         --------         ----

    TOTAL REVENUES
    --------------
     United States                     $805,408         $783,081          2.9
     International                    1,014,847        1,066,258         (4.8)
    --------------                    ---------        ---------         ----
    TOTAL                            $1,820,255       $1,849,339         (1.6)
    --------------                   ----------       ----------         ----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY SEGMENT AND GEOGRAPHIC AREA
    (Unaudited; Amounts in thousands)

                                             Nine Months ended June 30,
                                         2009             2008        % Change
                                         ----             ----        --------
    BD MEDICAL
    --------------
     United States                   $1,167,062       $1,149,717          1.5
     International                    1,558,285        1,640,722         (5.0)
    --------------                    ---------        ---------         ----
    TOTAL                            $2,725,347       $2,790,439         (2.3)
    --------------                   ----------       ----------         ----

    BD DIAGNOSTICS
    --------------
     United States                     $872,055         $840,695          3.7
     International                      774,156          766,050          1.1
    --------------                      -------          -------          ---
    TOTAL                            $1,646,211       $1,606,745          2.5
    --------------                   ----------       ----------          ---

    BD BIOSCIENCES
    --------------
     United States                     $325,926         $333,891         (2.4)
     International                      565,657          531,711          6.4
    --------------                      -------          -------          ---
    TOTAL                              $891,583         $865,602          3.0
    --------------                     --------         --------          ---

    TOTAL REVENUES
    --------------
     United States                   $2,365,043       $2,324,303          1.8
     International                    2,898,098        2,938,483         (1.4)
    --------------                    ---------        ---------         ----
    TOTAL                            $5,263,141       $5,262,786            -
    --------------                   ----------       ----------           --



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended June 30,
    (Unaudited; Amounts in thousands)

                                                    United States
                                       --------------------------------------
                                         2009             2008        % Change
                                         ----             ----        --------

    BD MEDICAL
    -------------------------
     Medical Surgical Systems          $256,171         $243,960          5.0
     Diabetes Care                       91,330           87,469          4.4
     Pharmaceutical Systems              43,460           49,125        (11.5)
     Ophthalmic Systems                   6,937            6,170         12.4
    -------------------------             -----            -----         ----
    TOTAL                              $397,898         $386,724          2.9
    -------------------------          --------         --------          ---

    BD DIAGNOSTICS
    -------------------------
     Preanalytical Systems             $155,760         $144,416          7.9
     Diagnostic Systems                 143,614          135,702          5.8
    -------------------------           -------          -------          ---
    TOTAL                              $299,374         $280,118          6.9
    -------------------------          --------         --------          ---

    BD BIOSCIENCES
    -------------------------
     Cell Analysis                      $70,518          $80,186        (12.1)
     Discovery Labware                   37,618           36,053          4.3
    -------------------------            ------           ------          ---
    TOTAL                              $108,136         $116,239         (7.0)
    --------------------------         --------         --------         ----

    TOTAL UNITED STATES                $805,408         $783,081          2.9
    --------------------------         --------         --------          ---



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended June 30, (continued)
    (Unaudited; Amounts in thousands)

                                              International
                            --------------------------------------------------
                                                          % Change
                                                 -----------------------------
                                                               FX         FX
                                2009       2008   Reported   Neutral    Impact
                                ----       ----   --------   -------    ------

    BD MEDICAL
    -------------------
     Medical Surgical
      Systems               $242,701     $272,064    (10.8)      3.1    (13.9)
     Diabetes Care            94,521       94,244      0.3      12.3    (12.0)
     Pharmaceutical
      Systems                220,503      230,346     (4.3)      8.3    (12.6)
     Ophthalmic Systems       13,048       14,770    (11.7)      0.1    (11.8)
    -------------------       ------       ------    -----       ---    -----
    TOTAL                   $570,773     $611,424     (6.6)      6.4    (13.0)
    -------------------     --------     --------     ----       ---    -----

    BD DIAGNOSTICS
    -------------------
     Preanalytical
      Systems               $136,427     $146,345     (6.8)      6.5    (13.3)
     Diagnostic Systems      130,578      126,959      2.9      13.0    (10.1)
    -------------------      -------      -------      ---      ----    -----
    TOTAL                   $267,005     $273,304     (2.3)      9.5    (11.8)
    -------------------     --------     --------     ----       ---    -----

    BD BIOSCIENCES
    -------------------
     Cell Analysis          $139,251     $141,889     (1.9)      3.0     (4.9)
     Discovery Labware        37,818       39,641     (4.6)      0.8     (5.4)
    -------------------       ------       ------     ----       ---     ----
    TOTAL                   $177,069     $181,530     (2.5)      2.5     (5.0)
    -------------------     --------     --------     ----       ---     ----

    TOTAL INTERNATIONAL   $1,014,847   $1,066,258     (4.8)      6.5    (11.3)
    -------------------   ----------   ----------     ----       ---    -----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Three Months Ended June 30, (continued)
    (Unaudited; Amounts in thousands)

                                                  Total
                            --------------------------------------------------
                                                           % Change
                                                  ----------------------------
                                                               FX         FX
                                2009       2008   Reported   Neutral    Impact
                                ----       ----   --------   -------    ------
    BD MEDICAL
    -------------------
     Medical Surgical
      Systems               $498,872     $516,024     (3.3)      4.0     (7.3)
     Diabetes Care           185,851      181,713      2.3       8.5     (6.2)
     Pharmaceutical
      Systems                263,963      279,471     (5.5)      4.8    (10.3)
     Ophthalmic Systems       19,985       20,940     (4.6)      3.7     (8.3)
    -------------------       ------       ------     ----       ---     ----
    TOTAL                   $968,671     $998,148     (3.0)      5.1     (8.1)
    -------------------     --------     --------     ----       ---     ----

    BD DIAGNOSTICS
    -------------------
     Preanalytical
      Systems               $292,187     $290,761      0.5       7.2     (6.7)
     Diagnostic Systems      274,192      262,661      4.4       9.3     (4.9)
    -------------------      -------      -------      ---       ---     ----
    TOTAL                   $566,379     $553,422      2.3       8.2     (5.9)
    -------------------     --------     --------      ---       ---     ----

    BD BIOSCIENCES
    -------------------
     Cell Analysis          $209,769     $222,075     (5.5)     (2.4)    (3.1)
     Discovery Labware        75,436       75,694     (0.3)      2.5     (2.8)
    -------------------       ------       ------     ----       ---     ----
    TOTAL                   $285,205     $297,769     (4.2)     (1.2)    (3.0)
    -------------------     --------     --------     ----      ----     ----

    TOTAL REVENUES        $1,820,255   $1,849,339     (1.6)      5.0     (6.6)
    -------------------   ----------   ----------     ----       ---     ----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Nine Months ended June 30,
    (Unaudited; Amounts in thousands)

                                                      United States
                                     ----------------------------------------
                                         2009             2008       % Change
                                         ----             ----       --------
    BD MEDICAL
    -------------------------
     Medical Surgical Systems          $754,776         $729,152         3.5
     Diabetes Care                      263,028          250,099         5.2
     Pharmaceutical Systems             129,177          151,882       (14.9)
     Ophthalmic Systems                  20,081           18,584         8.1
    -------------------------            ------           ------         ---
    TOTAL                            $1,167,062       $1,149,717         1.5
    -------------------------        ----------       ----------         ---

    BD DIAGNOSTICS
    -------------------------
     Preanalytical Systems             $452,426         $428,391         5.6
     Diagnostic Systems                 419,629          412,304         1.8
    -------------------------           -------          -------         ---
    TOTAL                              $872,055         $840,695         3.7
    -------------------------          --------         --------         ---

    BD BIOSCIENCES
    -------------------------
     Cell Analysis                     $219,668         $225,814        (2.7)
     Discovery Labware                  106,258          108,077        (1.7)
    -------------------------           -------          -------        ----
    TOTAL                              $325,926         $333,891        (2.4)
    -------------------------          --------         --------        ----

    TOTAL UNITED STATES              $2,365,043       $2,324,303         1.8
    -------------------------        ----------       ----------         ---



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Nine Months ended June 30, (continued)
    (Unaudited; Amounts in thousands)

                                             International
                          ----------------------------------------------------
                                                          % Change
                                                  ----------------------------
                                                                FX        FX
                                2009       2008   Reported    Neutral   Impact
                                ----       ----   --------    ------    ------
    BD MEDICAL
    -------------------
     Medical Surgical
      Systems               $697,178     $766,401     (9.0)      2.3    (11.3)
     Diabetes Care           271,221      269,215      0.7       8.8     (8.1)
     Pharmaceutical
      Systems                550,718      563,969     (2.3)      5.6     (7.9)
     Ophthalmic Systems       39,168       41,137     (4.8)      3.7     (8.5)
    -------------------       ------       ------     ----       ---     ----
    TOTAL                 $1,558,285   $1,640,722     (5.0)      4.5     (9.5)
    -------------------   ----------   ----------     ----       ---     ----

    BD DIAGNOSTICS
    -------------------
     Preanalytical
      Systems               $396,380     $408,031     (2.9)      7.2    (10.1)
     Diagnostic Systems      377,776      358,019      5.5      12.2     (6.7)
    -------------------      -------      -------      ---      ----     ----
    TOTAL                   $774,156     $766,050      1.1       9.5     (8.4)
    -------------------     --------     --------      ---       ---     ----

    BD BIOSCIENCES
    -------------------
     Cell Analysis          $450,615     $421,095      7.0       8.1     (1.1)
     Discovery Labware       115,042      110,616      4.0       4.4     (0.4)
    -------------------      -------      -------      ---       ---     ----
    TOTAL                   $565,657     $531,711      6.4       7.3     (0.9)
    -------------------     --------     --------      ---       ---     ----

    TOTAL INTERNATIONAL   $2,898,098   $2,938,483     (1.4)      6.4     (7.8)
    -------------------   ----------   ----------     ----       ---     ----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    REVENUES BY BUSINESS SEGMENTS AND UNITS
    Nine Months ended June 30, (continued)
    (Unaudited; Amounts in thousands)

                                                Total
                          ----------------------------------------------------
                                                             % Change
                                                    --------------------------
                                                                FX        FX
                                2009       2008     Reported  Neutral   Impact
                                ----       ----     --------  -------   ------
    BD MEDICAL
    -------------------
     Medical Surgical
      Systems             $1,451,954   $1,495,553       (2.9)     2.9    (5.8)
     Diabetes Care           534,249      519,314        2.9      7.1    (4.2)
     Pharmaceutical
      Systems                679,895      715,851       (5.0)     1.2    (6.2)
     Ophthalmic Systems       59,249       59,721       (0.8)     5.1    (5.9)
    -------------------       ------       ------       ----      ---    ----
    TOTAL                 $2,725,347   $2,790,439       (2.3)     3.3    (5.6)
    -------------------   ----------   ----------       ----      ---    ----

    BD DIAGNOSTICS
    --------------
     Preanalytical
      Systems               $848,806     $836,422        1.5      6.4    (4.9)
     Diagnostic Systems      797,405      770,323        3.5      6.6    (3.1)
    -------------------      -------      -------        ---      ---    ----
    TOTAL                 $1,646,211   $1,606,745        2.5      6.5    (4.0)
    -------------------   ----------   ----------        ---      ---    ----

    BD BIOSCIENCES
    -------------------
     Cell Analysis          $670,283     $646,909        3.6      4.3    (0.7)
     Discovery Labware       221,300      218,693        1.2      1.4    (0.2)
    -------------------      -------      -------        ---      ---    ----
    TOTAL                   $891,583     $865,602        3.0      3.6    (0.6)
    -------------------     --------     --------        ---      ---    ----

    TOTAL REVENUES        $5,263,141   $5,262,786          -      4.3    (4.3)
    -------------------   ----------   ----------          -      ---    ----



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL REVENUE INFORMATION
    SAFETY REVENUES
    (Unaudited; Amounts in thousands)

                                     Three Months Ended June 30,
                            --------------------------------------------------
                                                           % Change
                                                    --------------------------
                                                                FX       FX
                                2009        2008    Reported   Neutral  Impact
                                ----        ----    --------   -------  ------
    TOTAL SAFETY REVENUES
    ---------------------
     United States          $272,719     $261,041        4.5      4.5       -
     International           148,970      143,495        3.8     17.9   (14.1)
    ---------------------    -------      -------        ---     ----   -----
    TOTAL                   $421,689     $404,536        4.2      9.3    (5.1)
    ---------------------   --------     --------        ---      ---    ----



                                    Nine Months ended June 30,
                           ---------------------------------------------------
                                                          % Change
                                                    --------------------------
                                                                FX        FX
                                2009        2008    Reported   Neutral  Impact
                                ----        ----    --------   -------  ------
    TOTAL SAFETY REVENUES
    ---------------------
     United States           $796,714    $774,608        2.9      2.9       -
     International            419,768     390,797        7.4     18.7   (11.3)
    ---------------------     -------     -------        ---     ----   -----
    TOTAL                  $1,216,482  $1,165,405        4.4      8.2    (3.8)
    ---------------------  ----------  ----------        ---      ---    ----



    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS FISCAL 2009
    Revised for Home Health Care Discontinued Operations
    (Unaudited; Amounts in thousands, except per-share data)

                                          Quarter 1   Quarter 2  Quarter 2 YTD
                                          ---------   ---------  -------------
    REVENUES                            $1,717,919   $1,724,967    $3,442,886

    Cost of products sold                  796,274      829,350     1,625,624
    Selling and administrative             406,019      436,359       842,378
    Research and development                97,314       98,588       195,902
    ----------------------------------      ------       ------       -------
    TOTAL OPERATING COSTS AND EXPENSES   1,299,607    1,364,297     2,663,904
    ----------------------------------   ---------    ---------     ---------

    OPERATING INCOME                       418,312      360,670       778,982

    Interest income                          1,651        4,312         5,963
    Interest expense                        (7,824)      (7,495)      (15,319)
    Other income (expense), net              9,411       (5,701)        3,710
    ----------------------------------       -----       ------         -----

    INCOME FROM CONTINUING OPERATIONS
     BEFORE INCOME TAXES                   421,550      351,786       773,336

    Income tax provision                   112,131       92,612       204,743
    ----------------------------------     -------       ------       -------

    INCOME FROM CONTINUING OPERATIONS      309,419      259,174       568,593

    Income from Discontinued Operations
     before Income Tax                       3,503        2,726         6,229

    Income tax provision                       854          611         1,465
    -----------------------------------        ---          ---         -----

    INCOME FROM DISCONTINUED OPERATIONS      2,649        2,115         4,764
    -----------------------------------      -----        -----         -----

    NET INCOME                            $312,068     $261,289      $573,357
    -----------------------------------   --------     --------      --------

    EARNINGS PER SHARE

    Basic:
    Income from continuing
     operations                              $1.28        $1.08         $2.36
    Income from discontinued operations      $0.01        $0.01         $0.02
    Net income                               $1.29        $1.09         $2.38

    Diluted:
    Income from continuing operations        $1.25        $1.05         $2.30
    Income from discontinued operations      $0.01        $0.01         $0.02
    Net income                               $1.26        $1.06         $2.32


    AVERAGE SHARES OUTSTANDING

         Basic                             242,397      240,239       241,330
         Diluted                           248,311      245,890       247,436
    -----------------------------------    -------      -------       -------



    BECTON DICKINSON AND COMPANY
    SUPPLEMENTAL INFORMATION
    Revised for Home Health Care Discontinued Operations
    (Unaudited; Amounts in thousands, except per share data)

                                          Three Months Ended March 31, 2009
                                         ------------------------------------
                                             As      Litigation    Excluding
                                          Revised    Charge (1)       Item
                                         ---------  ------------   ----------

    Selling and administrative            $436,359      $(45,000)    $391,359
     as a % of revenues                       25.3%                      22.7%

    Operating Income                       360,670        45,000      405,670
     as a % of revenues                       20.9%                      23.5%

    Income taxes                            92,612        17,100      109,712
     effective tax rate                       26.3%                      27.7%

    Income from continuing operations      259,174        27,900      287,074
     as a % of revenues                       15.0%                      16.6%

    Diluted earnings per share
    -----------------------------------
    Income from continuing operations(2)     $1.05         $0.11        $1.17

    (1) Represents the charge relating to the pending settlement with the
        direct purchaser plaintiffs (which includes BD's distributors)
        in the antitrust class actions.
    (2) Total per share amounts may not add due to rounding.



                                          Six Months Ended March 31, 2009
                                         -------------------------------
                                              As      Litigation    Excluding
                                           Revised    Charge (1)       Item
                                          ---------  ------------   ----------

    Selling and administrative            $842,378      $(45,000)    $797,378
       as a % of revenues                     24.5%                      23.2%

    Operating Income                       778,982        45,000      823,982
       as a % of revenues                     22.6%                      23.9%

    Income taxes                            204,743       17,100      221,843
       effective tax rate                      26.5%                     27.1%

    Income from continuing operations       568,593       27,900      596,493
       as a % of revenues                      16.5%                     17.3%

    Diluted earnings per share
    ---------------------------------
    Income from continuing operations         $2.30        $0.11        $2.41


    (1) Represents the charge relating to the pending settlement with the
        direct purchaser plaintiffs (which includes BD's distributors)
        in the antitrust class actions.



    BECTON DICKINSON AND COMPANY
    CONSOLIDATED INCOME STATEMENTS FISCAL 2008
    Revised for Home Health Care Discontinued Operations
    (Unaudited; Amounts in thousands, except per-share data)

                         Quarter 1  Quarter 2  Quarter 3  Quarter 4    Year
                        ---------- ---------- ---------- ---------- ----------
    REVENUES           $1,687,077 $1,726,370 $1,849,339 $1,812,156 $7,074,942

    Cost of products
     sold                 820,005    841,073    905,388    880,372  3,446,838
    Selling and
     administrative       417,197    410,207    435,807    432,399  1,695,610
    Research and
     development           91,374     95,866     99,928    108,463    395,631
    -------------------    ------     ------     ------    -------    -------
    TOTAL OPERATING
     COSTS AND EXPENSES 1,328,576  1,347,146  1,441,123  1,421,234  5,538,079
    ------------------- ---------  ---------  ---------  ---------  ---------

    OPERATING INCOME      358,501    379,224    408,216    390,922  1,536,863

    Interest income        13,528     8,005     10,956      6,879     39,368
    Interest expense      (10,339)    (8,098)    (9,017)    (8,889)   (36,343)
    Other income
     (expense), net           707        828     (1,285)    (1,734)    (1,484)
    --------------------      ---        ---     ------     ------     ------

    INCOME FROM
     CONTINUING
     OPERATIONS BEFORE
      INCOME TAXES        362,397    379,959    408,870    387,178   1,538,404

    Income tax provision   95,028    106,418    112,875    108,216     422,537
    --------------------   ------    -------    -------    -------     -------

    INCOME FROM
     CONTINUING
      OPERATIONS          267,369    273,541    295,995    278,962   1,115,867

    Income from
     Discontinued
     Operations before
      Income Tax            5,213      3,234        833      4,434      13,714

    Income tax provision
     (benefit)              1,034        590       (261)     1,222       2,585
    --------------------    -----        ---       ----      -----       -----

    INCOME FROM
     DISCONTINUED
      OPERATIONS            4,179      2,644      1,094      3,212      11,129
    --------------------    -----      -----      -----      -----      ------

    NET INCOME           $271,548   $276,185   $297,089   $282,174  $1,126,996
    -------------------- --------   --------   --------   --------  ----------

    EARNINGS PER SHARE

    Basic: (1)
    Income from
     continuing
     operations              $1.09      $1.12      $1.21      $1.14      $4.57
    Income from
     discontinued
     operations              $0.02      $0.01         $-      $0.01      $0.05
    Net income               $1.11      $1.13      $1.22      $1.16      $4.61

    Diluted: (1)
    Income from
     continuing
     operations              $1.06      $1.08      $1.18      $1.11      $4.42
    Income from
     discontinued
     operations              $0.02      $0.01         $-      $0.01      $0.04
    Net income               $1.07      $1.09      $1.18      $1.12      $4.46


    AVERAGE SHARES
     OUTSTANDING

         Basic             244,292    244,869    244,273    243,863    244,323
         Diluted           253,116    252,788    251,648    251,197    252,681
    --------------------   -------    -------    -------    -------    -------

    (1) Total per share amounts may not add due to rounding.


'/>"/>
SOURCE BD (Becton, Dickinson and Company)
Copyright©2009 PR Newswire.
All rights reserved


Related medicine news :

1. Prepaid Emergency Travel Announces a Unique Service That Provides Peace of Mind During Family Emergencies
2. The Mills Group LLC Announces ElderCare/PrimePlus Service
3. Tampa Bay Radiation Oncology Announces New Full Service Center at Bruce B Downs
4. Kensey Nash Corporation Announces its Fourth Quarter and Fiscal Year End 2009 Earnings Release Date and Teleconference
5. Roxane Laboratories, Inc. Announces the Launch of Risperidone Oral Solution 1mg/mL
6. ISTA Pharmaceuticals Announces Conference Call and Webcast of Second Quarter 2009 Financial Results
7. Akorn, Inc. Announces Second Quarter 2009 Earnings Release and Conference Call Information
8. Stryker Announces Election of New Director
9. Birdies for Breast Cancer Announces Fifth Annual Charity Golf Classic Hosted by Top Womens Golfer, Cristie Kerr
10. ASTRO announces 2009 Fellows
11. Smith & Nephew Announces Launch of ACTICOAT Flex Wound Care Products in the USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/8/2016)... , ... February 08, 2016 , ... ... in Houma, LA, celebrates the beginning of a new charity campaign. As part ... Court Appointed Special Advocates (CASA). In the belief that children deserve a voice, ...
(Date:2/8/2016)... PISCATAWAY, N.J. (PRWEB) , ... February 08, 2016 ... ... of protective footwear and clothing, announced expansion into Canada to provide its range ... has opened a sales office in Quebec City that will provide bilingual customer ...
(Date:2/8/2016)... Atlanta, GA (PRWEB) , ... ... ... information technology and security executive networking and relationship-marketing firm, announced today that ... the 2016 Information Security Executive® (ISE®) West Awards. , Awards include ...
(Date:2/8/2016)... CA (PRWEB) , ... February 08, 2016 , ... ... showing greater than 50% lower incidence rate of type 2 diabetes in the ... averages. ”It is time to make a change in public health,” states Carole ...
(Date:2/8/2016)... ... February 08, 2016 , ... The schedule is now online ... The AutismOne 2016 Conference, which is being held May 25-29 at the Loews Chicago ... about helpful interventions and causes of chronic illness in children. , Very recent articles ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... the U.S. Food and Drug Administration (FDA) has ... for SB-318, a single treatment strategy intended to ... (MPS I). The SB-318 IND application is now ... 1/2 clinical study (SB-318-1502) designed to assess the ...
(Date:2/5/2016)... , Feb. 5, 2016  Despite the recent ... slower than other industries to embrace Big Data due ... utilization. On the medical side, organizations have begun looking ... from clinical trials to adherence. --> ... benchmarking firm Best Practices, LLC, Big Data has started ...
(Date:2/5/2016)... , Feb. 5, 2016  As people age, ... The multitude of recommended screenings and tests that are ... a priority. However, for the majority of aging individuals, ... health planning. For the 37.5 million American adults who ... the present to make hearing health a 2016 healthy ...
Breaking Medicine Technology: